参考文献/References:
[1] Wang W, Jiang B, Sun H, et al. Prevalence, incidence, and mortality of stroke in China: results from a nationwide Population-Based survey of 480 687 adults[J]. Circulation, 2017, 135(8): 759-771.
[2] Wang D, Liu J, Liu M, et al. Patterns of stroke between university hospitals and nonuniversity hospitals in mainland china: prospective multicenter hospital-based registry study[J]. World Neurosurg, 2017, 98(2): 258-265.
[3] 万敏,宋西方,贾伟华.急性脑梗死的血管再通研究进展[J].卒中与神经疾病,2021,28(1):110-113.
[4] 颜颂旭,王明珠,竺王玉,等.急性脑梗死患者血清中CD40L、白细胞介素18含量与患者神经功能损伤的关系[J].中国卫生检验杂志,2017,27(5):674-676.
[5] 魏妍妍,刘丹丹,朱金华,等.细胞因子与中枢神经系统疾病的研究[J].中国医学创新,2015,12(6):140-142.
[6] Prieto GA, Cotman CW. Cytokines and cytokine networks target neurons to modulate long-term potentiation[J]. Cytokine Growth Factor Rev, 2017, 34(2): 27-33.
[7] 刘全生,张雯凌.可溶性CD40L水平对急性脑梗死患者颈动脉粥样硬化斑块稳定性的影响[J].中国实用神经疾病杂志,2016,19(7):12-13.
[8] Yang LX, Chen FY, Yu HL, et al. Poncirin suppresses lipopolysaccharide(LPS)-induced microglial inflammation and ameliorates brain ischemic injury in experimental stroke in mice[J]. Ann Transl Med, 2020, 8(21): 1344.
[9] 啜红斐,郎桂艳,田步先.依达拉奉对急性脑梗死患者血清中白细胞介素-1、-17A和高迁移率族蛋白B1的影响[J].中国老年学杂志,2017,37(16):3977-3978.
[10] 程南方,谭峰,梁艳桂,等.急性脑梗死患者血清炎症因子与血瘀的多重线性回归分析[J].河南中医,2018,38(12):1841-1844.
[11] Malone K, Amu S, Moore AC, et al. Immunomodulatory therapeutic strategies in stroke[J]. Front Pharmacol, 2019, 10(无期号): 630.
[12] Lambertsen KL, Biber K, Finsen B. Inflammatory cytokines in experimental and human stroke[J]. J Cereb Blood Flow Metab, 2012, 32(9): 1677-1698.
[13] Basu A, Lazovic J, Krady JK, et al. Interleukin-1 and the interleukin-1 type 1 receptor are essential for the progressive neurodegeneration that ensues subsequent to a mild hypoxic/ischemic injury[J]. J Cereb Blood Flow Metab, 2005, 25(1): 17-29.
[14] Jin R, Liu L, Zhang S, et al. Role of inflammation and its mediators in acute ischemic stroke[J]. J Cardiovasc Transl Res, 2013, 6(5): 834-851.
[15] Diaz-Ca?stro C, Reiner MF, Bonetti NR, et al. AP-1(activated protein-1)transcription factor JunD regulates ischemia/reperfusion brain damage via IL-1β(interleukin-1β)[J]. Stroke, 2019, 50(2): 469-477.
[16] 姜伟韬,袁良津,施雪英.急性脑梗死患者发生神经功能缺损的程度与其体内炎症细胞因子水平的相关性研究[J].当代医药论丛,2018,16(10):124-126.
[17] El CC, Schwarzfischer L, Rehli M. Interleukin-4 induced interferon regulatory factor(Irf)4 participates in the regulation of alternative macrophage priming[J]. Immunobiology, 2010, 215(9/10): 821-825.
[18] Zhao R, Ying M, Gu S, et al. Cysteinyl leukotriene receptor 2 is involved in inflammation and neuronal damage by mediating microglia M1/M2 polarization through NF-κB pathway[J]. Neuroscience, 2019, 422(21): 99-118.
[19] Ting SM, Zhao X, Zheng X, et al. Excitatory pathway engaging glutamate, calcineurin, and NFAT upregulates IL-4 in ischemic neurons to polarize microglia[J]. J Cereb Blood Flow Metab, 2020, 40(3): 513-527.
[20] Perego C, Fumagalli S, Miteva K, et al. Combined genetic deletion of IL(interleukin)-4, IL-5, IL-9, and IL-13 does not affect ischemic brain injury in mice[J]. Stroke, 2019, 50(8): 2207-2215.
[21] Sasaguri T, Arima N, Tanimoto A, et al. A role for interleukin 4 in production of matrix metalloproteinase 1 by human aortic smooth muscle cells[J]. Atherosclerosis, 1998, 138(2): 247-253.
[22] Lee YW, Hirani AA. Role of interleukin-4 in atherosclerosis[J]. Arch Pharm Res, 2006, 29(1): 1-15.
[23] Kassem KM, Ali M, Rhaleb NE. Interleukin 4: its role in hypertension, atherosclerosis, valvular, and nonvalvular cardiovascular diseases[J]. J Cardiovasc Pharmacol Ther, 2020, 25(1): 7-14.
[24] Liu X, Liu J, Zhao S, et al. Interleukin-4 is essential for microglia/macrophage M2 polarization and Long-Term recovery after cerebral ischemia[J]. Stroke, 2016, 47(2): 498-504.
[25] 桂千,程庆璋.炎症因子与急性脑梗死的相关性研究[J].中国实用神经疾病杂志,2015,18(20):42-43.
[26] 何诺,谢林森,董丽,等.炎症因子表达及凝血相关指标检验对急性进展性脑梗死患者病情评估的效果分析[J].山西医药杂志,2020,49(24):3483-3485.
[27] 鲁建华,虞冬辉.急性脑梗死与炎症的关系探讨[J].中国实用神经疾病杂志,2017,20(2):24-26.
[28] Pawluk H, Woz’niak A, Grzes’k G, et al. The role of selected Pro-Inflammatory cytokines in pathogenesis of ischemic stroke[J]. Clin Interv Aging, 2020, 15(无期号): 469-484.
[29] 张帆,卢红,王传升,等.多种脂肪细胞因子与脑梗死患者颈动脉粥样硬化斑块稳定性的关系[J].中风与神经疾病杂志,2013,30(8):685-688.
[30] Yoshida M, Kato N, Uemura T, et al. Time dependent transition of the levels of protein-conjugated acrolein(PC-Acro), IL-6 and CRP in plasma during stroke[J]. eNeurologicalSci, 2017, 7(1): 18-24.
[31] Fahmi RM, Elsaid AF. Infarction size, interleukin-6, and their interaction are predictors of Short-Term stroke outcome in young Egyptian adults[J]. J Stroke Cerebrovasc Dis, 2016, 25(10): 2475-2481.
[32] Zhang L, Xu D, Zhang T, et al. Correlation between interleukin-6, interleukin-8, and modified early warning score of patients with acute ischemic stroke and their condition and prognosis[J]. Ann Palliat Med, 2021, 10(1): 148-155.
[33] Gr?h? MH, Clausen BH, Fenger CD, et al. Beneficial potential of intravenously administered IL-6 in improving outcome after murine experimental stroke[J]. Brain Behav Immun, 2017, 65(5): 296-311.
[34] Kowalska K, Klimiec E, Weglarczyk K, et al. Reduced ex vivo release of pro-inflammatory cytokines and elevated plasma interleukin-6 are inflammatory signatures of post-stroke delirium[J]. J Neuroinflammation, 2018, 15(1): 111.
[35] Dammanahalli JK, Wang X, Sun Z. Genetic interleukin-10 deficiency causes vascular remodeling via the upregulation of Nox1[J]. J Hypertens, 2011, 29(11): 2116-2125.
[36] Garcia JM, Stillings S, Leclerc JL, et al. Role of interleukin-10 in acute brain injuries[J]. Front Neurol, 2017, 8(2): 244.
[37] Ormstad H, Aass HC, Lund-S?ensen N, et al. Serum levels of cytokines and C-reactive protein in acute ischemic stroke patients, and their relationship to stroke lateralization, type, and infarct volume[J]. J Neurol, 2011, 258(4): 677-685.
[38] Rong T, He M, Hua Y, et al. Associations of interleukin 10, matrix metallopeptidase 9, and legumain with blood pressure variability and neurologic outcomes in patients with ischemic stroke[J]. Int J Gen Med, 2020, 13(1): 1595-1602.
[39] Liu N, Chen R, Du H, et al. Expression of IL-10 and TNF-alpha in rats with cerebral infarction after transplantation with mesenchymal stem cells[J]. Cell Mol Immunol, 2009, 6(3): 207-213.
[40] Jenny NS, Callas PW, Judd SE, et al. Inflammatory cytokines and ischemic stroke risk: The REGARDS cohort[J]. Neurology, 2019, 92(20): e2375-e2384.
[41] Zhou L, Zhu X, Wang J, et al. Association between interleukin-18(137G/C and 607C/A)gene polymorphisms and risk of ischemic stroke: a meta-analysis[J]. Neuroreport, 2019, 30(2): 89-94.
[42] Wang Q, Yu D, Liang J, et al. Significance of expression of AIM2, IL-1β, and IL-18 in plasma of patients with acute cerebral infarction[J]. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2021, 46(2): 149-155.
[43] Bahrami A, Sathyapalan T, Sahebkar A. The role of interleukin-18 in the development and progression of atherosclerosis[J]. Curr Med Chem, 2021, 28(9): 1757-1774.
[44] Hao Y, Ding J, Hong R, et al. Increased interleukin-18 level contributes to the development and severity of ischemic stroke[J]. Aging(Albany NY), 2019, 11(18): 7457-7472.
[45] Luo Q, Fan Y, Lin L, et al. Interleukin-33 protects ischemic brain injury by regulating specific microglial activities[J]. Neuroscience, 2018, 385(18): 75-89.
[46] Li XM, Wang XY, Feng XW, et al. Serum interleukin-33 as a novel marker for long-term prognosis and recurrence in acute ischemic stroke patients[J]. Brain Behav, 2019, 9(9): e01369.
[47] Qian L, Yuanshao L, Wensi H, et al. Serum IL-33 is a novel diagnostic and prognostic biomarker in acute ischemic stroke[J]. Aging Dis, 2016, 7(5): 614-622.
[48] Guo S, Luo Y. Brain Foxp3+ regulatory T cells can be expanded by Interleukin-33 in mouse ischemic stroke[J]. Int Immunopharmacol, 2020, 81(4): 106027.
[49] Zhou Z, Zhang J, Li X, et al. Protein microarray analysis identifies key cytokines associated with malignant middle cerebral artery infarction[J]. Brain Behav, 2017, 7(8): e00746.